Skip to main
EVH

Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health (EVH) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Evolent Health Inc. is poised for robust growth, as evidenced by its projected $10-15 million sequential EBITDA improvements in both Q3 and Q4, setting a strong earnings trajectory with $32.5 million anticipated in Q3 and $45 million in Q4. The company's legacy Performance Suite Medical Expense Ratio is expected to enhance by 500 basis points to 89%, reflecting operational efficiency and cost management. Furthermore, with significant top-line growth expected for 2026 and a pathway to normalized margins of 7-10%, Evolent Health positions itself for outsized growth potential in the coming years, supported by its foundational strengths in value-based care and specialty services.

Bears say

The financial excerpts indicate a concerning outlook for Evolent Health, primarily due to a significant projected decline in revenue stemming from a loss of approximately $100 million from their legacy Performance Suite business. This revenue loss occurs amidst broader market challenges, as clients exit and rationalize their positions, which could exacerbate future earnings contraction. Furthermore, the company has downgraded its earnings per share estimates for FY2026 and FY2027, highlighting ongoing pressure on both profitability and operational efficiency.

Evolent Health (EVH) has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolent Health (EVH) Forecast

Analysts have given Evolent Health (EVH) a Buy based on their latest research and market trends.

According to 14 analysts, Evolent Health (EVH) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolent Health (EVH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.